Research and Development Projects Sample Clauses

Research and Development Projects. Any material research and development projects to be undertaken by QA will be subject to approval of CLMI's Board of Directors.
Sample 1Sample 2
AutoNDA by SimpleDocs
Research and Development Projects. 62 SCHEDULE K ..................................................................................................................................... 63
Sample 1
Research and Development Projects. Schedule ‎4.9.14 contains a list of all material research and development projects currently in progress which are conducted or proposed to be conducted by the Company.
Sample 1
Research and Development Projects. 5.1. The Parties shall consider during the Term proposals to work jointly on research and/or development projects for bonding wire development (“R&D Projects”). The Parties shall meet at least once each calendar year to propose and discuss R&D Projects. Either Party may provide the other Party with a written proposal for an R&D Project. The proposal shall set out a deadline of at least sixty (60) days to respond in writing as to whether the other Party wishes to participate on the R&D Project. If the Party receiving the proposal elects to participate in the R&D Project, the Parties shall use reasonable best efforts to agree upon the terms and conditions for the R&D Project, including the activities and materials to be provided by each Party, how the costs and expenses will be borne by the Parties, and whether a royalty will be paid by one party to the other. Any such royalty shall be agreed upon by the Parties prior to work beginning on a proposed R&D Project. The Parties will meet at least quarterly to review the progress of accepted R&D Projects.
Sample 1
Research and Development Projects. ‎Section 3.16(u) of the Company Disclosure Schedule contains a list of all material research and development projects currently in progress which are conducted or proposed to be conducted by the Company.
Sample 1
Research and Development Projects. Add the following paragraphs at the end of Section 3.01 as follows: "During the Term of the Agreement, the parties shall meet no less frequently than annually at a mutually agreeable time and place at which MEMC shall advise PHC of the nature of any major research or pilot plant projects within the Field of this Agreement which MEMC is undertaking. In addition, during the Term of the Agreement, MEMC shall periodically advise PHC of the status and progress of projects in the Field of the Agreement which MEMC has undertaken via its "Product and Process Pipeline" program (the program under which MEMC currently directs its research and development activities) or any similar successor program. During the Term of this Agreement, if PHC requests information regarding a technical improvement or development of MEMC (either product or process-related) within the Field of the Agreement and PHC and MEMC agree that PHC has a commercial requirement for such information, then MEMC will make available to PHC the necessary technical information if MEMC has incorporated the improvement or development into any of its Plants. If MEMC has not incorporated the improvement or development into any of its Plants, the parties will either agree for MEMC to transfer the information to PHC at a later stage of development or for PHC to participate in the development. PHC may undertake its own research or pilot plant projects provided such projects (i) are not duplicative of any MEMC projects, (ii) are mutually beneficial, and (iii) are agreed upon by both parties."
Sample 1
Research and Development Projects 
Sample 1Sample 2
AutoNDA by SimpleDocs

Related to Research and Development Projects

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Clinical Development (a) Stellartech shall design, develop and construct a Clinical Unit for each of the Thermage Disposable Device and the Thermage Generator, and any required component or subassembly thereof and shall deliver such Clinical Units to Thermage in accordance with the Development Program; (b) Stellartech shall deliver to Thermage such other Deliverables as are contemplated by the Development Program in accordance with the Development Program; and (c) as requested by Thermage and automatically at the conclusion of the Development Program, Stellartech, so long as Thermage is not in breach of its material obligation hereunder, shall deliver in writing to Thermage any and all data and information held by or in the control of Stellartech which is necessary or useful to obtain regulatory approval of the Products in the United States or any foreign country.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Information Systems Acquisition Development and Maintenance a. Client Data – Client Data will only be used by State Street for the purposes specified in this Agreement.

  • Creation and Development Fee If the Prospectus related to a Trust specifies a creation and development fee, the Trustee shall, on or immediately after the end of the initial offering period, withdraw from the Capital Account, an amount equal to the unpaid creation and development fee as of such date and credit such amount to a special non-Trust account designated by the Depositor out of which the creation and development fee will be distributed to the Depositor (the "Creation and Development Account"). The creation and development fee is the per unit amount specified in the Prospectus for the Trust.

  • Joint Development All inventions, know-how, trade secrets, data or information which result from joint development by the Parties hereto shall be jointly owned by the Parties. The Parties hereby agree to cooperate in good faith in the filing of any and all patent applications in all jurisdictions.

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Neither the Investor nor any Affiliate of the Investor shall have, in the prior thirty (30) days, published or distributed any research report (as such term is defined in Rule 500 of Regulation AC) concerning the Company.

Time is Money Join Law Insider Premium to draft better contracts faster.